EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
06 nov. 2023 07h00 HE
|
EvolveImmune
BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
30 oct. 2023 09h07 HE
|
INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
18 oct. 2023 07h00 HE
|
EvolveImmune
EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023
Machine Learning Model Unveils Stunning Lung Cancer Risk Predictions
05 oct. 2023 11h58 HE
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- In a recent groundbreaking study published on October 3rd in the open access journal PLOS Medicine, Thomas Callender of University College London and his...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
03 oct. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Interim results for the six months ended 30 June 2023
29 sept. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
21 sept. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Global NSCLC Market Dynamics and Innovations: Striving to Transform Lung Cancer Treatment
05 sept. 2023 09h51 HE
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company...
Global NSCLC Market Dynamics and Innovations: Striving to Transform Lung Cancer Treatment
05 sept. 2023 09h49 HE
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
28 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...